MDxHealth (NASDAQ: MDXH) grants CCO John Bellano 333,000 share options

Rhea-AI Filing Summary

MDxHealth SA granted Chief Commercial Officer John Bellano a total of share options covering ordinary shares at an exercise price of $0.76 per share. One grant of 217,000 options vests based on Company performance criteria, while a separate 116,000-option grant vests in three equal annual installments from the grant date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Bellano John

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Share Option	116,000	$0.00	--
Grant/Award	Share Option	217,000	$0.00	--

Holdings After Transaction: Share Option — 116,000 shares (Direct, null)

Footnotes (1)

1. Represents options to purchase ordinary shares at a price per share of $0.76 granted on June 1, 2026. The options vest upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods. Represents options to purchase ordinary shares at a price per share of $0.76 granted on June 1, 2026 . The options vest in three equal installments on each of the first three anniversaries of the date of grant.

Key Figures

Performance-based options granted: 217,000 options Time-based options granted: 116,000 options Exercise price: $0.76 per share +3 more

6 metrics

Performance-based options granted 217,000 options Share options with performance-criteria vesting granted on June 1, 2026

Time-based options granted 116,000 options Share options vesting in three equal annual installments from June 1, 2026

Exercise price $0.76 per share Exercise price for both MDxHealth option grants

Combined option grants 333,000 options Derived sum of 217,000 and 116,000 options granted to John Bellano

Option expiration date May 28, 2036 Scheduled expiration for both sets of granted options

Transaction price per option $0.00 Reported transaction price per share option in the grants

Key Terms

Share Option, exercise price, performance criteria, vest in three equal installments, +1 more

5 terms

Share Option financial

"Represents options to purchase ordinary shares at a price per share of $0.76"

exercise price financial

"options to purchase ordinary shares at a price per share of $0.76"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

performance criteria financial

"The options vest upon the achievement of certain Company performance criteria evaluated by the Board"

vest in three equal installments financial

"The options vest in three equal installments on each of the first three anniversaries"

expiration date financial

"expiration_date": "2036-05-28T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bellano John

(Last) (First) (Middle)

CAP BUSINESS CENTER

ZONE INDUSTRIELLE DES HAUTS-SARTS

(Street)

HERSTAL BELGIUM 4040

(City) (State) (Zip)

BELGIUM

(Country)

2. Issuer Name and Ticker or Trading Symbol
MDxHealth SA [ MDXH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$0.76	06/01/2026		A		116,000		(1)	05/28/2036	Ordinary Shares	116,000	$0	116,000	D
Share Option	$0.76	06/01/2026		A		217,000		(2)	05/28/2036	Ordinary Shares	217,000	$0	217,000	D

Explanation of Responses:

1. Represents options to purchase ordinary shares at a price per share of $0.76 granted on June 1, 2026. The options vest upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.

2. Represents options to purchase ordinary shares at a price per share of $0.76 granted on June 1, 2026 . The options vest in three equal installments on each of the first three anniversaries of the date of grant.

	/s/ Mark Busch, as attorney-in-fact for John Bellano	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did MDXH Chief Commercial Officer John Bellano receive in this Form 4 filing?

John Bellano received two grants of share options to acquire MDxHealth ordinary shares. One grant covers 217,000 options and another 116,000 options, both with an exercise price of $0.76 per share and different vesting conditions.

What are the vesting conditions for John Bellano's MDXH performance-based options?

The 217,000 MDxHealth share options vest only if certain Company performance criteria are achieved. These criteria are evaluated by the Board of Directors at the end of the relevant performance periods, tying vesting directly to the Company’s measured operating results.

How do the time-based MDXH options granted to John Bellano vest?

The 116,000 time-based MDxHealth share options vest in three equal installments. Vesting occurs on each of the first three anniversaries of the June 1, 2026 grant date, rewarding continued service over that three-year period.

What is the exercise price and expiration date of John Bellano’s MDXH options?

Both MDxHealth option grants to John Bellano carry an exercise price of $0.76 per ordinary share. According to the filing, these options are scheduled to expire on May 28, 2036, providing a long-term window for potential exercise.

Are John Bellano’s MDXH option grants open-market purchases or compensation awards?

These MDxHealth option grants are classified as awards under transaction code “A,” described as a grant, award, or other acquisition. The transaction price per option is reported as $0.00, indicating compensation-related awards rather than open-market purchases.